Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
-
Cancer Care
- Diagnosing Cancer
-
Our Cancer Programs »
- Adolescent and Young Adult Cancer Program
- Blood Cancer & Hematological Malignancy Program
- Blood Disorder (Hematology) Program
- Breast Cancer Program
- Cancer Risk Reduction and Education Clinic
- Cardio-Oncology Program
- Cancer Genetics Program
- Childhood Cancer Survivorship Program
- Endocrine Tumor Program
- Eye Cancer Program
- Gastrointestinal (GI) Cancer Program
- Genitourinary Cancer Program
- Gynecologic Oncology Program
- Head and Neck Cancer Program
- Liver Tumor and Cancer Program
- Lung Cancer Program
- Neuro-Oncology (Brain Tumor) Program
- Neurofibromatosis Program
- Pediatric Neuro-Oncology Program
- Pediatric Oncology Program
- Pediatric Sarcoma Program
- Pediatric Thrombosis Program
- Radiation Oncology
- Sarcoma Cancer Program
- Skin Cancer Program
- Cancer Survivorship Program »
-
Cancer Prevention and Screenings »
- Cervical Cancer Screening Guidelines
- Colorectal Cancer Screening
- Endometrial (Uterine) Cancer Screening Guidelines
- Hepatitis and Cancer
- HPV Vaccine and Screenings
- Liver Cancer Guidelines
- Lung Cancer Screening
- Mammogram
- Ovarian Cancer Screening Guidelines
- Prostate Cancer Screening Guidelines
- Skin Cancer Screenings
- Sun and Skin Safety
- Tobacco Use and Cancer
- Cancer Treatments
- Cancer Types
- About Us »
-
Cancer Care »
- Diagnosing Cancer
-
Our Cancer Programs »
- Adolescent and Young Adult Cancer Program
- Blood Cancer & Hematological Malignancy Program
- Blood Disorder (Hematology) Program
- Breast Cancer Program
- Cancer Risk Reduction and Education Clinic
- Cardio-Oncology Program
- Cancer Genetics Program
- Childhood Cancer Survivorship Program
- Endocrine Tumor Program
- Eye Cancer Program
- Gastrointestinal (GI) Cancer Program
- Genitourinary Cancer Program
- Gynecologic Oncology Program
- Head and Neck Cancer Program
- Liver Tumor and Cancer Program
- Lung Cancer Program
- Neuro-Oncology (Brain Tumor) Program
- Neurofibromatosis Program
- Pediatric Neuro-Oncology Program
- Pediatric Oncology Program
- Pediatric Sarcoma Program
- Pediatric Thrombosis Program
- Radiation Oncology
- Sarcoma Cancer Program
- Skin Cancer Program
- Cancer Survivorship Program »
-
Cancer Prevention and Screenings »
- Cervical Cancer Screening Guidelines
- Colorectal Cancer Screening
- Endometrial (Uterine) Cancer Screening Guidelines
- Hepatitis and Cancer
- HPV Vaccine and Screenings
- Liver Cancer Guidelines
- Lung Cancer Screening
- Mammogram
- Ovarian Cancer Screening Guidelines
- Prostate Cancer Screening Guidelines
- Skin Cancer Screenings
- Sun and Skin Safety
- Tobacco Use and Cancer
- Cancer Treatments
- Cancer Types
- Clinical Trials and Research »
- Donate and Volunteer »
- Education »
- Patients and Families »
- Appointments »
- Doctors and Locations »
- Avanzando Caminos (Leading Pathways) Study »
- Community Outreach and Engagement Program »
- Estudio Avanzando Caminos (Leading Pathways) »
Principal Investigator
Andrew Brenner, MD, PhD, is a professor of medicine in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio, specializing in breast cancer and brain and spinal cord cancers. He is internationally acclaimed for advancing novel therapies to treat breast cancers and central nervous system tumors, alongside his active clinical practice.
About this study
ReSPECT-GBM is an FDA-approved Phase 2 clinical trial sponsored by Plus Therapeutics, Inc. and is supported by the U.S. National Institutes of Health. The objective is to determine the safety and efficacy of a single administration of a new targeted radiation therapy, Rhenium (Re186) Obisbemeda, in adult patients diagnosed with recurrent glioblastoma.
The Phase 2 clinical study involves placing a catheter into the tumor during a needle biopsy. The following day, patients receive an infusion of the radiation-containing particles directly through the catheter into the tumor. The catheter is then removed on the third day, and patients are discharged home for outpatient follow-up.
The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific disease as it remains an investigational treatment.
NATIONAL TRIAL REFERENCE NUMBER | NCT01906385
When speaking with your physician, please have the national trial reference number available.
Learn more about this clinical trial
Participation eligibility
Researchers look for people who fit a certain description, which is called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
To qualify
- Must be age 18 or older
- Have recurrent glioblastoma after previously receiving radiation and chemotherapy
- Be able to undergo an MRI scan
- Have not taken Avastin medication in the past
Contact the study team
Now enrolling
Participate in a clinical trial for adults with recurrent glioblastoma.